April 7, 2026 issue of JAMA

JAMA’s April 7, 2026 issue highlights two randomized clinical trials that could matter for day-to-day medical practice.

One study evaluates intravenous tenecteplase for acute non-large vessel occlusion ischemic stroke in the late treatment window, between 4.5 and 24 hours after symptom onset. JAMA’s media materials say the trial found better 90-day functional outcomes, but also a higher risk of symptomatic intracranial hemorrhage.

The issue also includes a randomized trial of radiation treatment for patients with 5 to 20 brain metastases. JAMA’s article page and research summary say stereotactic radiation performed better than hippocampal-avoidance whole brain radiation on symptom burden and daily-function interference.

Both studies were published online earlier in the year, but they now appear in the April 7 print issue and are part of the journal’s latest weekly package of research.

The issue underscores how JAMA continues to publish practice-relevant randomized evidence across neurology, oncology and stroke care.